These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6087417)

  • 1. On the multiplicity of platelet prostaglandin receptors. II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogs.
    Tynan SS; Andersen NH; Wills MT; Harker LA; Hanson SR
    Prostaglandins; 1984 May; 27(5):683-96. PubMed ID: 6087417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors.
    Town MH; Casals-Stenzel J; Schillinger E
    Prostaglandins; 1983 Jan; 25(1):13-28. PubMed ID: 6302737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
    Hamid-Bloomfield S; Whittle BJ
    Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor.
    Thierauch KH; Stürzebecher CS; Schillinger E; Rehwinkel H; Radüchel B; Skuballa W; Vorbrüggen H
    Prostaglandins; 1988 Jun; 35(6):855-68. PubMed ID: 2847246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets.
    Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1979 Jul; 210(1):134-40. PubMed ID: 221643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry.
    Andersen NH; Eggerman TL; Harker LA; Wilson CH; De B
    Prostaglandins; 1980 May; 19(5):711-35. PubMed ID: 6252573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of prostaglandin D2 with prostacyclin, carbacyclin and the hydantoin prostaglandin, BW245C, in guinea-pig platelets.
    Hamid S; Whittle BJ
    Br J Pharmacol; 1985 May; 85(1):285-90. PubMed ID: 2992652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist.
    Giles H; Leff P; Bolofo ML; Kelly MG; Robertson AD
    Br J Pharmacol; 1989 Feb; 96(2):291-300. PubMed ID: 2924081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
    Keery RJ; Lumley P
    Br J Pharmacol; 1988 Jul; 94(3):745-54. PubMed ID: 2460179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
    Whittle BJ; Moncada S; Vane JR
    Prostaglandins; 1978 Sep; 16(3):373-88. PubMed ID: 364545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue.
    Whittle BJ; Moncada S; Mullane K; Vane JR
    Prostaglandins; 1983 Feb; 25(2):205-23. PubMed ID: 6344147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostaglandins and platelet aggregation.
    Smith JB
    Acta Med Scand Suppl; 1981; 651():91-9. PubMed ID: 7034481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antagonism by BW A868C of PGD2 and BW245C activation of human platelet adenylate cyclase.
    Trist DG; Collins BA; Wood J; Kelly MG; Robertson AD
    Br J Pharmacol; 1989 Feb; 96(2):301-6. PubMed ID: 2466517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mechanism of heterologous desensitization of adenylate cyclase: prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets.
    Ashby B
    Mol Pharmacol; 1990 Jul; 38(1):46-53. PubMed ID: 1695318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
    Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
    Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the characterisation of prostanoid receptors: a proposed classification.
    Kennedy I; Coleman RA; Humphrey PP; Levy GP; Lumley P
    Prostaglandins; 1982 Nov; 24(5):667-89. PubMed ID: 6131499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The binding of 6-oxo-prostaglandin E1 to platelet prostanoid receptors.
    Jaschonek K; Renn W; Weisenberger H
    Prostaglandins Leukot Med; 1986 Sep; 24(1):79-86. PubMed ID: 3020591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.